Opportunity for Investors to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
Investors in Edwards Lifesciences Corporation (NYSE: EW) have a chance to take the lead on a securities fraud lawsuit. The Rosen Law Firm, a global investor rights law firm, is reminding individuals who purchased Edwards securities between February 6, 2024, and July 24, 2024, that the deadline to become the lead plaintiff is December 13, 2024.
If you bought Edwards securities during this period, you may be eligible for compensation without having to pay any out-of-pocket fees. To participate in the class action lawsuit, visit the Rosen Law Firm website or contact Phillip Kim, Esq. by phone or email. It’s important to act before the December 13th deadline if you wish to serve as the lead plaintiff.
The lawsuit alleges that during the Class Period, Edwards provided misleading information about its expected revenue for fiscal year 2024, specifically concerning the growth of its core product, Transcatheter Aortic Valve Replacement (TAVR). When the true details came to light, investors allegedly suffered financial losses.
The Rosen Law Firm has a strong track record in securities class actions, having secured significant settlements for investors in the past. Investors are encouraged to choose qualified counsel with experience and resources to lead the litigation effectively.
To learn more about joining the Edwards class action lawsuit or to get updates, visit the Rosen Law Firm’s website or follow them on social media. Remember, until a class is certified, you have the choice to select your own counsel or remain an absent class member.
Investors interested in potential recovery from the lawsuit should stay informed and consider their options carefully. Whether you choose to take an active role in the case or not, it’s essential to understand how your investments may be impacted.
